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Summary
 
Death receptor–mediated apoptosis can be modulated by several antiapoptotic proteins, such as
the FLICE (FADD [Fas-associated death domain]-like IL-1
 
b
 
–converting enzyme)-inhibitory
proteins (FLIPs). The FLIP family includes both cellular and viral members. The Kaposi’s sar-
coma–associated herpesvirus protein (KSHV)-FLIP is expressed by human herpesvirus 8 (HHV-8),
which is associated with malignancies such as Kaposi’s sarcoma and certain lymphomas. In this
paper, we demonstrate that KSHV-FLIP protects cells from Fas-mediated apoptosis by inhibit-
ing caspase activation and permits clonal growth in the presence of death stimuli in vitro. Fur-
thermore, we show that KSHV-FLIP can act as a tumor progression factor by promoting tumor
establishment and growth in vivo. When injected into immunocompetent recipient mouse
strains, murine B lymphoma cells (A20) transduced with KSHV-FLIP rapidly develop into
aggressive tumors showing a high rate of survival and growth. The tumor-progressive activity
of KSHV-FLIP is mediated by prevention of death receptor–induced apoptosis triggered by
conventional T cells. Consequently, inhibitors of death receptor signaling can be regarded as a
new class of tumor progression factors, and HHV-8–associated tumors may represent naturally
occurring examples of the tumorigenic effect of such inhibitors.
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A
 
poptosis is a highly regulated mechanism that plays a
pivotal role in the physiology of organisms and possibly
participates in the defence against pathogens and cancer. Cell
death can be induced through engagement of the death re-
ceptors belonging to the TNFR superfamily (TNFR-1,
Fas/Apo1/CD95, DR3/Apo3, DR4, and DR5/Apo2) (1).
Upon death receptor ligation, intracellular adapter molecules,
such as Fas-associated death domain (FADD)/MORT-1
(mediator of receptor-induced toxicity),
 
1
 
 TRADD (TNFR1-
associated death domain protein), RIP (receptor interact-
ing protein), and RAIDD (RIP-associated ICH-1/CED-3–
homologous protein with a death domain) are recruited via
death domain interactions (1, 2). These molecules can in turn
associate with and activate the upstream caspases through
death effector domain (DED) or caspase recruitment do-
main (CARD)
 
 
 
interactions, leading to the activation of the
downstream caspases and thus resulting in effective cell
death (2, 3).
Excessive or impaired cell death strongly correlates to
many disorders (4). Therefore, in normal physiology, the
apoptotic machinery must be strictly controlled at several
levels to avoid dysregulated cell death. Intracellularly, this
control is exerted through several antiapoptotic proteins,
many of them targeting the caspases. Interestingly, some vi-
ruses have adopted similar strategies to prevent cell death by
expressing viral counterparts to these modulators of apop-
tosis, allowing extended viral replication (5). Viral FLICE
(FADD [Fas-associated death domain]-like IL-1
 
b
 
–convert-
ing enzyme)-inhibitory proteins (FLIPs), found in several
herpesviruses (5, 6), and their cellular homologues (cFLIPs) (7)
constitute a novel class of antiapoptotic proteins that pre-
vent the association of the upstream caspases 8 and 10 with the
adapter molecule FADD through DED–DED interactions.
Another major pathway for induction of cell death,
caused by various types of cellular stress, involves the Bcl-2
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Abbreviations used in this paper:
 
 BCBL, body cavity–based B cell lym-
phoma; DED, death effector domain; FADD, Fas-associated death do-
main; FLICE, FADD-like IL-1
 
b
 
–converting enzyme; FLIP, FLICE-
inhibitory protein; KSHV, Kaposi’s sarcoma–associated herpesvirus;
TUNEL, TdT-mediated dUTP–biotin nick-end labeling. 
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family (8). The antiapoptotic protein Bcl-2 was originally
discovered as an oncogenic protein in a follicular B cell
lymphoma (9). The dual role of Bcl-2 as both an inhibitor
of cell death and an oncogenic protein could perhaps apply
to other regulators of apoptosis, for instance the proteins
counteracting death receptor signaling. We therefore decided
to test the hypothesis that proteins that interfere with death
receptor–mediated apoptosis can be involved in tumor de-
velopment. We chose to study the human herpesvirus 8
(HHV-8) gene FLIP, also referred to as Kaposi’s sarcoma–
associated herpesvirus FLIP (
 
KSHV-FLIP
 
), 
 
K13l
 
, or 
 
ORF71
 
for the following reasons. First, KSHV-FLIP is postulated to
elicit antiapoptotic activities (6). Second, HHV-8 has been
implicated in Kaposi’s sarcoma pathogenesis as well as pri-
mary effusion lymphoma or body cavity–based B cell lym-
phoma (BCBL) and multicentric Castleman’s syndrome in
HIV-infected patients (10). Hence, we sought to determine
the possible involvement of KSHV-FLIP in tumor establish-
ment and growth.
 
Materials and Methods
 
Cell Lines and Mice.
 
Mouse B and T lymphoma cell lines A20
and L5178Y (mock and FasL transfectant) and the human retroviral
packaging cell line phoenix-ampho (available at http://www.uib.
no/mbi/nolan/NL-phoenix.html) were grown as described (11, 12).
A20 is derived from a spontaneous reticulum cell neoplasm found in
an old BALB/c mouse (11). Sex- and age-matched (4–6 wk old)
inbred BALB/c, (BALB/c 
 
3
 
 C57BL/6) F
 
1
 
, C57BL/6, and C.B-
17SCID mice were obtained from Charles River Labs.
 
 
 
Mice were
maintained in the animal facility at the University of Stockholm.
 
Expression Vectors, Cell Transduction, and Cloning.
 
KSHV-FLIP
was amplified by PCR from the BCBL-1 cell line, established from
a 
 
BCBL
 
 (13) using the oligonucleotides K13EcoU 5
 
9
 
-ACTGGA-
ATTCATGGCCACTTACGAGGTTCTCTG-3
 
9
 
 and K13BamL
5
 
9
 
-CATGGGATCCCTATGGTGTATGGCGATAGTGTTG-3
 
9
 
.
The fragment was inserted into the EcoRI and BamHI sites of
the retroviral expression vector pLXSN (14) and then used to
transiently transfect the phoenix-ampho packaging cell line. Super-
natants containing recombinant viral particles were used for retro-
viral transduction of A20 cells. Stable G418-resistant clones were
obtained by limiting dilution. Mock and KSHV-FLIP–expressing
clones were identified by RT-PCR, and the presence of helper
virus was excluded by PCR amplification of viral 
 
env
 
 using the
primers 5
 
9
 
-ACCTGGAGAGTCACCAACC-3
 
9
 
 and 5
 
9
 
-TACTT-
TGGAGAGGTCGTAGC-3
 
9
 
.
 
Apoptosis and Limiting Dilution Assays.
 
Sensitivity of mock and
KSHV-FLIP clones to Fas-mediated apoptosis was assessed by
treating 10
 
6
 
 cells with 40 ng/ml of the anti–mouse Fas mAb Jo2
(PharMingen) for 24 h at 37
 
8
 
C. Alternatively, the human retrovi-
ral packaging cell line phoenix-ampho was transfected with the
FasL-hCD8
 
a
 
/pSG5 vector encoding the soluble mouse FasL,
and 5 
 
3
 
 10
 
5
 
 A20 cells were cultured with 1:16 diluted soluble
FasL supernatant or 1:2 diluted supernatant from nontransfected
 
f
 
A cells in a total volume of 1 ml for 24 h at 37
 
8
 
C. Apoptosis
was also induced with membrane-bound FasL by mixing mock-
or mouse FasL-transfected L5178Y cells with 2 
 
3
 
 10
 
5
 
 A20 cells
at an E/T ratio of 1:4 for 24 h at 37
 
8
 
C. Cells were then stained
with propidium iodide and annexin-V-fluos (Boehringer Mann-
heim) according to the manufacturer’s instructions, and apoptosis
 
was monitored by flow cytometry analysis. The mock- and
KSHV-FLIP–transduced A20 cell lines and clones were treated
with 200 ng/ml of the Fas antibody in a limiting dilution assay for
12 d at 37
 
8
 
C, and the frequency of clonal growth was determined
by visual inspection on day 12 and calculated as described (15).
 
Flow Cytometry Analysis.
 
The expression of Fas on the mock-
and KSHV-FLIP–transduced A20 clones was evaluated by incubat-
ing 10
 
6
 
 cells with 1:100 PE-conjugated hamster anti–mouse Fas (Jo2)
or 1:100 of an isotype-matched control in the presence of 1:100
anti–mouse CD16/CD32 (Fc-block). Dead cells and debris were
excluded from the analysis by gating in forward and side scatter.
 
Determination of Caspase Activity.
 
6 
 
3
 
 10
 
6 
 
cells of mock and
KSHV-FLIP clones (c)11 and 17 were subjected to 40 ng/ml of
the anti–mouse Fas mAb Jo2 for 20, 40, 60, or 120 min at 37
 
8
 
C.
Cells were then washed twice in PBS and immediately frozen in
liquid nitrogen and stored at 
 
2
 
80
 
8
 
C. DEVD- (caspase-3), IETD-
(caspase-8), and LEHD-AMC (amino-methyl-coumarin; caspase-9)
cleavage was measured using a protocol adopted from Nicholson et
al. (16). DEVD- and IETD-AMC were obtained from the Pep-
tide Institute, Inc., and LEHD-AMC was purchased from En-
zyme Systems Products. Cell lysates (10
 
6
 
)
 
 
 
and 50 
 
m
 
M substrate
were mixed in a reaction buffer (100 mM Hepes for DEVD-AMC
and IETD-AMC or 100 mM 2-(
 
N
 
-morpholino)-ethanesulfonic
acid for LEHD-AMC, 10% sucrose, 0.1% 3-[(3-cholamidopro-
pyl) dimethylammonio] propane-1-sulphonic acid [CHAPS], 5 mM
dithiothreitol, and 10
 
2
 
6
 
% NP-40, pH 7.2 for DEVD- and IETD-
AMC and pH 6.8 for LEHD-AMC) and dispensed in duplicate in
a microtiter plate. The cleavage of the fluorogenic peptide sub-
strates was monitored by AMC liberation in a Fluoroscan II plate
reader (Labsystems) at an excitation wavelength of 380 nm and an
emission wavelength of 460 nm. Fluorescence was measured every
70 s for 30 min. The fluorescence units were converted to pico-
moles of AMC using a standard curve obtained with free AMC,
and the data was analyzed by linear regression.
 
Injection of Mice.
 
Groups of four to eight BALB/c or
(BALB/c 
 
3
 
 C57BL/6) F
 
1
 
 mice were injected subcutaneously in
the interscapular region with 2.5 
 
3 
 
10
 
5
 
, 10
 
6
 
, or 4 
 
3
 
 10
 
6 
 
mock- or
KSHV-FLIP–transduced A20 cells. Three groups of four C57BL/6
mice were injected subcutaneously in the interscapular region with
4 
 
3
 
 10
 
6
 
 mock or KSHV-FLIP clones 11 and 17. Two groups of
six C.B-17SCID mice were injected subcutaneously in the inter-
scapular region with 10
 
6
 
 mock- or KSHV-FLIP–transduced A20
cells (KSHV-FLIPc11). Tumor growth was monitored every sec-
ond day for 110 d for BALB/c, (BALB/c 
 
3
 
 C57BL/6) F
 
1
 
, and
C57BL/6 and daily for 25 d for C.B-17SCID mice. Tumors
were measured using a caliper, and the square root of each tumor
area was calculated. Mice were killed with CO
 
2
 
 when the tumors
had reached the maximal allowed size of 
 
z
 
1 cm, as decided by
the Stockholm Ethical Committee for Animal Experiments, or
when the experiment was terminated. Tumor samples were ob-
tained by surgical excision and frozen at 
 
2
 
70
 
8
 
C or fixed in a 4%
solution of paraformaldehyde and then processed to paraffin
blocks. All material was cut into 6-
 
m
 
m-thick sections. The frozen
material was mounted on Super Frost microscope slides (Menzel-
Glaser), fixed in cold acetone for 10 min, and stored at 
 
2
 
20
 
8
 
C
until use for immunostaining. Paraffin sections were mounted on
glass slides and used for morphological evaluation after hematoxy-
lin and eosin staining or after immunohistochemistry.
 
Immunofluorescence and TdT-mediated dUTP–Biotin Nick-End La-
beling Assays.
 
Frozen sections were immunostained for mouse an-
tigens using rat primary antibodies specific for B cell (ID3, B220),
cytotoxic T cell (Lyt 2), and macrophage markers (Mac 3), and an
avidin–biotin complexes–peroxidase detection system was used ac- 
1027
 
Djerbi et al.
cording to the manufacturer’s specifications (Vector Labs., Inc.).
Bound antibodies were developed with 1 mg/ml diaminobenzidine
(Sigma Chemical Co.) followed by counterstaining the slides with
Meyer hematoxylin, and they were evaluated by light microscope.
The percentage of apoptosis in the tumor samples was determined
by TdT-mediated dUTP–biotin nick-end labeling (TUNEL). The
TUNEL reaction was carried out by using an in situ cell death de-
tection kit (Boehringer Mannheim) according to the manufacturer’s
indications, followed by Meyer hematoxylin counterstaining.
 
Results and Discussion
 
To assess the antiapoptotic property of KSHV-FLIP in
vitro
 
,
 
 KSHV-FLIP was cloned into the retroviral expres-
sion vector pLXSN, followed by transduction of a Fas-sen-
sitive subclone of the B lymphoma cell line A20. Two
clones (KSHV-FLIPc11 and -c17) and a mock clone were
chosen for further studies and tested for sensitivity to apop-
tosis induced by the agonistic anti-Fas mAb Jo2 or by solu-
ble or membrane-bound Fas ligand. KSHV-FLIP conferred
almost complete protection against Fas-mediated apoptosis,
whereas the mock clone was as sensitive as the wild-type
A20 cell line (Fig. 1). The expression level of the Fas re-
ceptor (Fig. 2) and the proliferation rate (data not shown)
were similar between sensitive and resistant clones, indicat-
ing that the difference in Fas sensitivity is not due to differ-
ential expression of Fas and that KSHV-FLIP confers no
growth advantage to the cells in vitro. Limiting dilution
analysis showed that KSHV-FLIP–positive cells were able
to form clones in the presence of anti-Fas mAb at a fre-
quency between 1/11 and 1/37, whereas the correspond-
ing frequencies for the mock-transduced cells were be-
tween 1/5,000 and 1/27,000 (Table I). Previous reports
have established that the FLIP proteins prevent death re-
ceptor–mediated apoptosis by impeding the activity of the
upstream caspases 8 and 10 (6, 7), resulting in a disruption
of the signal through the caspase cascade and, consequently,
a suppression of the activity of the downstream caspases.
The mechanism of action of KSHV-FLIP in the KSHV-
FLIP clones 11 and 17 was therefore investigated by moni-
toring IETD-like activity (caspase-8), LEHD-like activity
(caspase-9), and DEVD-like activity (caspase-3) in vitro in
a continuous fluorometric assay. The mock and KSHV-
FLIP clones 11 and 17 were challenged with 40 ng/ml of
the mouse anti–Fas mAb Jo2 and collected at different time
points for measurement of AMC release (Fig. 3). The ac-
tivity of caspase-8 was almost completely blocked in the
presence of KSHV-FLIP (Fig. 3 A). Similar results were
obtained measuring caspase-9– and caspase-3–like activities
(Fig. 3, B and C). Some caspase-3–like activity was, how-
ever, observed in the KSHV-FLIP clones but was signifi-
cantly lower and delayed in time (Fig. 3 C). We have thus
shown that KSHV-FLIP can act as an antiapoptotic protein
in vitro by interfering with caspase activity, as anticipated
from previous reports on other members of the FLIP family
(6, 7). Furthermore, KSHV-FLIP allowed clonal cell
growth in the continuous presence of death stimuli. As
KSHV-FLIP presumably inhibits apoptosis through inter-
action with death effector domain–containing proteins, it is
likely that it can interfere with death signals from other
death receptors as well.
We wanted to test the role of KSHV-FLIP in tumor
progression in vivo. Therefore, the mock and KSHV-FLIP
A20 clones 11 and 17 were injected subcutaneously into
two recipient mouse strains, BALB/c (syngeneic) and
(BALB/c 
 
3
 
 C57BL/6) F
 
1
 
 (semiallogeneic), and tumor
growth was monitored for 110 d. The semiallogeneic sys-
tem was chosen to assess whether expression of KSHV-
Figure 1. KSHV-FLIP protects against Fas-induced apoptosis in vitro.
Sensitivity of mock and KSHV-FLIP clones to Fas-mediated apoptosis was
assessed by treating cells with the anti–mouse Fas mAb Jo2, soluble (s)FasL1
or sFasL2 (mock sFasL) fA supernatant, or membrane-bound (m)FasL- or
mock-transfected L5178Y cells (mock mFasL) (see Materials and Methods).
After 24 h at 378C, cells were stained with propidium iodide and annexin-
V-fluos, and apoptosis was monitored by flow cytometry analysis.
Figure 2. The expression level of the Fas recep-
tor is similar between the mock- and KSHV-FLIP–
transduced A20 clones. Flow cytometry analysis
was carried out as described in Materials and Meth-
ods using a Fas-specific antibody (thick line) and an
isotype-matched control (thin line). 
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FLIP would be involved in the so-called hybrid resistance
to parental tumors, possibly comprising NK cells (17). The
results are shown in Table II and summarized in Fig. 4.
The frequency of tumor appearance in BALB/c recipient
mice was dramatically higher for KSHV-FLIP– than for
mock-transduced cells (90 and 89% for c17 and c11 versus
32% for mock; Fig. 4 A). A similar pattern was seen in the
semiallogeneic mice (88 and 65% for c17 and c11 versus
17% for mock; Fig. 4 B). In addition, tumor appearance
was delayed in mice injected with mock-transduced cells
compared with mice injected with KSHV-FLIP–trans-
duced clones. This holds true both in the syngeneic and
semiallogeneic systems (Fig. 4, A and B). Compared with
the mock tumors, the KSHV-FLIP tumors reached the
maximally allowed size of 1 cm with a higher frequency in
both recipient strains (67 and 50% for c11 and c17 versus
11% for mock in BALB/c; 81 and 60% for c17 and c11
versus 11% for mock in [BALB/c 
 
3
 
 C57BL/6] F
 
1
 
). Fur-
thermore, the KSHV-FLIP tumors grew faster: 
 
z
 
45 d after
injection, most KSHV-FLIP tumors had progressed to a
size of 1 cm and mice had to be killed. In contrast, the few
progressive mock tumors attained a similar size first after
70–90 d after injection, as shown in Fig. 4, C and D. These
data strongly suggest that KSHV-FLIP promotes tumor es-
tablishment and progression in vivo and significantly in-
creases uncontrolled growth of the tumor. The tumor-pro-
moting property of KSHV-FLIP was, however, not
sufficient to allow tumor establishment upon injection of 4 
 
3
 
10
 
6
 
 cells in a completely allogeneic tumor–host system.
In contrast to the tumor cells transduced with KSHV-
FLIP, most mock cells were rejected shortly after appear-
ance in both mice strains. This prompted us to determine
the nature of the immune response that is triggered and ac-
counts for the elimination of the A20 tumor cells, against
which KSHV-FLIP confers protection. Tumor samples
were therefore stained for cell markers of B and T cells and
macrophages. Histologically, the tumors appeared to be
homogeneous growing tumors of large, undifferentiated
lymphoid cells staining positively for B cell markers, con-
firming their origin as A20 cells. 5–30% of the cells within
the tumors showed typical markers for macrophages. In tu-
mors resulting from injection of KSHV-FLIP–transduced
cells, 
 
,
 
5% CTLs were observed, whereas the CTL infiltra-
tion in the mock tumors was more evident (5–30%). The
percentage of apoptotic cells by TUNEL was higher in
mock-transduced (2%) than in KSHV-FLIP tumors (0.5%)
(data not shown). To investigate the role of conventional T
cells and NK-like cells in tumor clearance, KSHV-FLIPc11
and mock were injected into BALB/c congenic C.B-
17SCID mice lacking both the B and T cell compartments
due to a recombination deficiency. KSHV-FLIP– as well as
mock-transduced cells developed tumors with similar ki-
netics and size in all mice injected (Fig. 5, A and B). As B
cells are normally not involved in the rejection of solid tu-
mors (18), we conclude that conventional T cells, rather
than NK-like cells, are necessary for the rejection of A20
 
Table I.
 
Results from Limiting Dilution Assays
 
Cell line
Frequency of clonable cells in the
presence of mAb anti-Fas (Jo2)
A20 pLXSN (mock) 1/27,000
A20 KSHV-FLIP 1/37
A20 clone 1 (mock) 1/5,000
A20 KSHV-FLIP clone 11 1/11
A20 KSHV-FLIP clone 17 1/29
KSHV-FLIP allows clonal growth in the continuous presence of death
stimuli. All A20 cell clones and the mock- and KSHV-FLIP–transduced
cell lines were treated with 200 ng/ml of Fas antibody in a limiting dilu-
tion assay for 12 d at 37°C, and the frequency of clonal growth was de-
termined by visual inspection on day 12 and calculated as described (15).
Figure 3. KSHV-FLIP inhibits caspase-3–, caspase-8–, and caspase-9–like activities in Fas-triggered A20 cells. Mock (h) and KSHV-FLIPc11 (d) and
-c17 (m) were treated with the anti–mouse Fas mAb Jo2 and cleavage of the peptide substrates IETD-, LEHD-, and DEVD-AMC was measured using a
fluorogenic assay according to the procedure described in Materials and Methods. Time course of (A) IETD-AMC–like (caspase-8), (B) LEHD-AMC–like
(caspase-9), and (C) DEVD-AMC–like (caspase-3) processing in Fas-stimulated mock- and KSHV-FLIP– transduced A20 cells is shown. Means and SE
of duplicate samples have been calculated. 
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tumor cells. The results suggest that T cells may have a role
in immunosurveillance of death receptor–positive tumors.
However, the observation that the frequency of tumor
growth was somewhat lower in the semiallogeneic situa-
tion (Fig. 4, A and B) suggests that NK-like cells may par-
ticipate in the rejection of tumor cells lacking KSHV-
FLIP.
Our work formally demonstrates that KSHV-FLIP can
function as a tumor progression factor by blocking signal-
ing through death receptors and thereby protecting the tu-
mors against rejection mediated by conventional T cells.
Mechanistically, this inhibition of apoptosis is shown by
our data to be mediated through direct prevention of
caspase-8 activation and subsequent inhibition of caspases 3
and 9. The kinetics of caspase-8 induction is very rapid,
and caspase-3 activation is delayed as expected. Interest-
ingly, caspase-9 activity is appearing as quickly as caspase-8
activity. This finding may suggest an involvement of the
mitochondrial pathway in Fas-mediated apoptosis induced
in A20 cells. In fact, it has previously been described that
 
Table II.
 
Results from the Injections of Mock- and KSHV-FLIP–transduced A20 Cells (KSHV-FLIP Clones 11 and 17) in BALB/c and 
(BALB/c 
 
3
 
 C57BL/6) F
 
1
 
 Mice
 
Recipient strain
No. of
cells
Cell type
A20 mock A20 clone 11 A20 clone 17
No. of mice with tumors/no. of injected mice
BALB/c 4 
 
3
 
 10
 
6
 
2/4 3/3 4/4
10
 
6
 
2/8 8/8 6/8
2.5 
 
3
 
 10
 
5
 
2/7 6/8 8/8
(BALB/c 
 
3
 
 C57BL/6) F
 
1
 
4 
 
3
 
 10
 
6 0/2 4/4 4/4
106 1/8 5/8 3/5
2.5 3 105 2/8 5/8 8/8
Figure 4. KSHV-FLIP promotes tumor establishment and progression
in vivo. Groups of four to eight BALB/c or (BALB/c 3 C57BL/6) F1
mice were injected subcutaneously in the interscapular region with three
different concentrations of mock- or KSHV-FLIP–expressing A20 cells
(KSHV-FLIPc11 and -c17). Occurrence of tumors was monitored every
second day for 110 d. Tumor sizes were measured using a caliper, and the
square root of the tumor area was calculated. Mice were killed when tu-
mors had reached the maximal allowed size of z1 cm. The number of
BALB/c (A) and (BALB/c 3 C57BL/6) F1 (B) mice developing tumors
and the number of BALB/c (C) and (BALB/c 3 C57BL/6) F1 (D) mice
killed due to large tumor size is shown.
Figure 5. KSHV-FLIP– and mock-transduced A20 tumor cells grow
equally well in C.B-17SCID mice. Two groups of six mice were injected
subcutaneously in the interscapular region with mock- or KSHV-FLIP–
expressing A20 cells (KSHV-FLIPc11). Occurrence of tumors was moni-
tored every day for 25 d. Tumor sizes were measured using a caliper, and
the square root of the tumor area was calculated. Mice were killed when
tumors had reached the maximal allowed size of z1 cm. The number of
mice developing tumors (A) and the number of killed mice due to large
tumor size (B) are plotted against time.1030 Role of FLIP in Tumor Progression
Fas-induced apoptosis through caspase-8 can be enhanced
by release of cytochrome c and the induction of the
caspase-9 pathway (19). Therefore, the classification of cells
into types I and II based on the apoptotic pathway (via the
death-inducing signaling complex or mitochondria) prefer-
entially used by cells undergoing Fas-induced cell death
(20) cannot be applied to the A20 B lymphoma cells used
in this study.
The tumor-progressive activity of KSHV-FLIP not only
provides insight into the role of this protein in pathogenesis
of KSHV infection but also defines the family of inhibitors
of death receptor signaling as a new class of tumor progres-
sion factors. To date, this family includes viral and cellular
FLIPs and is likely to grow. It is expected from our data
that dysregulated expression of inhibitors of death receptor
signaling, such as the cellular FLIPs, will also be involved in
tumor formation and progression in humans. Interestingly,
the long form of cellular FLIP (cFLIPL) is reported to be
upregulated in human metastatic melanoma tumors (7),
compatible with a role for FLIP proteins in nonviral tum-
origenesis. In addition, the apoptosis inhibitor survivin,
which is structurally similar to the baculovirus inhibitor of
apoptosis protein, has been shown to be highly expressed in
cells of several common human cancers such as lung, colon,
pancreas, prostate, and breast cancer and in z50% of high-
grade non-Hodgkin’s lymphomas (21).
The newly discovered TRAIL (TNFR-related apopto-
sis-inducing ligand) receptors 1 and 2 (TRAILR-1/DR4
and TRAILR-2/DR5) have been reported to play an im-
portant role in the clearance of tumors (22). As the FLIPs
have been reported to inhibit TRAIL signaling (6, 7), this
sensitivity to TRAIL-induced apoptosis can be due to the
fact that tumor cells express lower levels of FLIP, as ob-
served in human melanoma cells (23). This would predict
that tumors expressing high levels of FLIP would be partic-
ularly aggressive. In fact, the inhibition of death receptor
signaling by loss of Fas receptor expression on certain tu-
mors can enable and enhance metastatic progression (24).
Further knowledge of the role of inhibitors of death re-
ceptor signaling in tumorigenesis is needed to comprehend
the complex process that leads to malignancy so as to de-
velop efficient diagnostic and therapeutic strategies.
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